

AVASTIN™

Saturday 5 June

16.30–16.45
La Louisiane Ballroom (hall A lobby)

Integrated education session: Targeting cancer: antibodies versus small molecules Abstract 2001

Phase II trial of erlotinib (OSI-774), an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor, and bevacizumab, a recombinant humanized monoclonal antibody to vascular endothelial growth factor (VEGF), in patients (pts) with metastatic breast cancer (MBC)

M DICKLER

HERCEPTIN®

Saturday 5 June

08.00–12.00
Hall A (right half)

General poster session: Breast cancer Abstract 608, poster number C4

Dose-dense and sequential combination of epirubicin and cyclophosphamide followed by paclitaxel and gemcitabine ± trastuzumab as neoadjuvant chemotherapy in stage II and III breast cancer. A phase II and pharmacogenomic study
P SANCHEZ-ROVIRA

Abstract 630, poster number E4

A multi-centre phase II trial of pegylated liposomal doxorubicin and trastuzumab in HER-2 over-expressing metastatic breast cancer (MBC)
SK CHIA

Abstract 636, poster number E10

Evaluation of vinorelbine (N) and trastuzumab (H) as first-line therapy for patients (pts) with HER2-positive metastatic breast cancer (HER2+ MBC): impact on clinical response and cardiac function
V GUILLEM PORTA

Abstract 642, poster number F5

Survival analysis from two open-label non-randomized phase II trials of trastuzumab (H) combined with docetaxel (T) and platinum (C, cisplatin or carboplatin) (TCH) in women with HER2+ advanced breast cancer (ABC)
D SLAMON

Abstract 643, poster number F6

First line treatment with weekly docetaxel, vinorelbine, and trastuzumab in HER2 overexpressing metastatic breast cancer (HER2+ MBC): a Minnie Pearl Cancer Research Network phase II trial
DA YARDLEY

Abstract 655, poster number G7

Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease
J ZIDAN

Abstract 670, poster number H11

Results of a 10-year retrospective search in two university institutes of pathology: concordance of HER-2/neu expression of primary breast carcinomas and their metachronous distant metastases
D LUFTNER

Abstract 674, poster number J4

Patient benefit from trastuzumab plus a taxane regardless of estrogen receptor (ER) status or prior adjuvant therapy for HER2+ metastatic breast cancer (MBC)
JC REDDY

Abstract 680, poster number J10

Clinical benefit of trastuzumab (H) among patients with HER2-positive metastatic breast cancer (MBC) not achieving objective responses when treated with H plus chemotherapy (CT)
CH YEON

13.00–17.00
275 (Escalators 5 & 6)

Poster discussion: Tumor biology and human genetics

Abstract 9522, poster number 14

Co-expression of ErbB family members in human breast cancer: Her-2/neu is the preferred dimerization candidate in nodal-positive tumors
CF SINGER

Abstract 9523, poster number 15

Cyclin D1 (CD1), interleukin-6 (IL-6), Ki67, transforming growth factor beta type II receptor, HER-2 and prediction of relapse in women with early stage breast cancer (BC) taking tamoxifen
HB MUSS

15.30–15.45
Hall H

Oral presentation: Breast cancer II Abstract 512

CALGB 9840: phase III study of weekly (W) paclitaxel (P) via 1-hour (h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC
AD SEIDMAN

16.00–16.15

Abstract 567

HER2 testing by local, central, and reference laboratories in the NCCTG N9831 Intergroup adjuvant trial
EA PEREZ

Sunday 6 June

08.00–12.00
Hall A (right half)

General poster session: Tumor biology and human genetics

Abstract 9562, poster number BB2

The predictive value of HER2 and p53 on outcomes after paclitaxel chemotherapy for metastatic breast cancer: results from CALGB 9342
NU LIN

14.30–14.45
Hall F

Oral presentation: Breast cancer I Abstract 520

Significantly higher pathological complete remission (PCR) rate following neoadjuvant therapy with trastuzumab (H), paclitaxel (P), and anthracycline-containing chemotherapy (CT): Initial results of a randomized trial in operable breast cancer (BC) with HER2 positive disease
AU BUZDAR

Monday 7 June

08.00–12.00
Hall A (right half)

General poster session: Developmental therapeutics: molecular therapeutics Abstract 3045, poster number L6

Targeting ErbB receptor interactions: a phase I trial of trastuzumab and erlotinib in metastatic HER2+ breast cancer
C BRITTEN

08.00–12.00
Hall A (right half)

Poster discussion: Breast cancer II Abstract 567, poster number 13

HER2 testing by local, central, and reference laboratories in the NCCTG N9831 Intergroup adjuvant trial
EA PEREZ

Abstract 569, poster number 15

Chromogen in situ hybridisation (CISH) for HER2 assessment is highly concordant with FISH in core cut biopsies of primary T2 breast cancers
GH RAAB

Abstract 570, poster number 16

Effects of trastuzumab (H) and chemotherapy on circulating HER2 extracellular domain (ECD) in patients with metastatic breast cancer (MBC) and non-small cell lung cancer (NSCLC)
B LEYLAND-JONES

AVASTIN™**Saturday 5 June**

13.00–17.00

Hall A (right half)

General poster session: Gastrointestinal (colorectal) cancer**Abstract 3528, poster number D1**

Bevacizumab does not increase bleeding in patients with metastatic colorectal cancer receiving concurrent anticoagulation

J HAMBLETON

Abstract 3529, poster number D2

Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) does not increase the incidence of venous thromboembolism when added to first-line chemotherapy to treat metastatic colorectal cancer

WF NOVOTNY

Abstract 3530, poster number D3

Lack of effect of bevacizumab on wound healing/bleeding complications when given 28–60 days following primary cancer surgery

F SCAPPATICCI

Abstract 3589, poster number J7

Phase I study of neoadjuvant bevacizumab, 5-fluorouracil, and radiation therapy followed by surgery for patients with primary rectal cancer

CG WILLETT

Abstract 3616, poster number M1

Bevacizumab in combination with 5-FU/leucovorin improves survival in patients with metastatic colorectal cancer: a combined analysis

RD MASS

Abstract 3617, poster number M2

Bevacizumab plus irinotecan/5-FU/leucovorin for treatment of metastatic colorectal cancer results in survival benefit in all pre-specified patient subgroups

GA FYFE

Sunday 6 June

08.00–12.00

291

(Escalator 7)

Poster discussion: Developmental therapeutics: molecular therapeutics**Abstract 3017, poster number 8**

Bowel perforation and fistula formation in colorectal cancer patients treated on Eastern Cooperative

Oncology Group (ECOG) studies E2200 and E3200

BJ GIANTONIO

08.00–12.00

R06

(2nd floor – escalators 1 & 2)

Poster discussion: Gastrointestinal (colorectal) cancer**Abstract 3515, poster number 6**

Bevacizumab (BV) plus 5-FU/leucovorin (FU/LV) for advanced colorectal cancer (CRC) that progressed after standard chemotherapies: an NCI Treatment Referral Center trial (TRC-0301)

HX CHEN

Abstract 3516, poster number 7

Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) to prolong progression-free survival in first-line colorectal cancer (CRC) in subjects who are not suitable candidates for first-line CPT-11

FF KABBINAVAR

Abstract 3517, poster number 8

Post-progression therapy (PPT) effect on survival in AVF2107, a phase III trial of bevacizumab in first-line treatment of metastatic colorectal cancer (mCRC)

E HEDRICK

11.30–11.45

R06

(2nd floor – escalators 1 & 2)

Poster discussion: Gastrointestinal (colorectal) cancer

Steps toward understanding the role of bevacizumab in the treatment of colorectal cancer

EK BERGSLAND

Monday 7 June

08.00–12.00

Hall A (right half)

General poster session: Developmental therapeutics: molecular therapeutics**Abstract 3041, poster number L2**

Clinical pharmacokinetics of bevacizumab following every 2- or every 3-week dosing

J GAUDREAU

09.30–10.45

271

(Escalators 5 & 6)

Special session: High-priority cooperative group phase III trials for community practitioners

Clinical trials: NSABP C-08: a clinical trial comparing infusional 5-FU plus oxaliplatin (mFOLFOX4) every two weeks with bevacizumab to the same regimen without bevacizumab for the treatment of patients with resected stages II and III carcinoma of the colon

G YOTHERS, CJ ALLEGRA, L FEHRENBACHER

TARCEVA™**Saturday 5 June**

13.00–17.00

Hall A (right half)

General poster session: Gastrointestinal (colorectal) cancer**Abstract 3580, poster number H9**

Phase II study of capecitabine, oxaliplatin and erlotinib in previously treated patients with metastatic colorectal cancer (MCRC)

JA MEYERHARDT

Abstract 3585, poster number J3

A phase 1b dose-escalation trial of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer (MCRC) patients

JP DELORD

XELODA®**Saturday 5 June**

13.00–17.00

Hall A (right half)

General poster session: Gastrointestinal (colorectal) cancer**Abstract 3534, poster number D7**

Capecitabine/irinotecan (CapIri) and capecitabine/oxaliplatin (CapOx) are active second-line protocols in patients with advanced colorectal cancer (ACRC) after failure of first-line combination therapy: results of a randomized phase II study

A GROTHEY

Abstract 3538, poster number D11

Capecitabine (X) chemoradiation (CRT) in the preoperative treatment of patients (pts) with rectal adenocarcinomas: a phase II GERCOR trial

O DUPUIS

Abstract 3540, poster number E2

A phase II study of capecitabine (CAP) and pre-operative radiation therapy (RT) in resectable, locally advanced rectal cancer (LARC)

A DE PAOLI

Abstract 3546, poster number E8

Phase III trial of infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment in advanced colorectal carcinoma (ACRC): results of an interim safety analysis

H-T ARKENAU

Abstract 3552, poster number F3

A phase II study of preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with locally advanced rectal adenocarcinoma

LR DUCK

13.00–17.00

Hall A (right half)

General poster session: Gastrointestinal (colorectal) cancer

Abstract 3555, poster number F6

XELOX (capecitabine plus oxaliplatin), a safe and active first-line regimen for elderly patients with metastatic colorectal cancer (MCRC): post-hoc analysis of a large phase II study
C TWELVES

Abstract 3559, poster number F10

Phase-II-study of preoperative chemoradiation with capecitabine in rectal cancer
J DUNST

Abstract 3562, poster number G2

Phase II study of short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) in patients with progressive colorectal cancer after irinotecan and 5-fluorouracil (FU) treatment
P PFEIFFER

Abstract 3567, poster number G7

A phase II study of capecitabine (X) in elderly patients (p) as 1st line treatment for patients (pts) with advanced or metastatic colorectal cancer (MCRC)
J FELIÚ

Abstract 3575, poster number H4

Preliminary phase II SOCRATES study results: capecitabine (CAP) combined with oxaliplatin (OX) and preoperative radiation (RT) in patients (pts) with locally advanced rectal cancer (LARC).
R GLYNN-JONES

Abstract 3578, poster number H7

Capecitabine (X) is resource saving compared with i.v. bolus 5-FU/LV in adjuvant chemotherapy for Dukes' C colon cancer patients: medical resource utilization (MRU) data from a large phase III trial (X-ACT)
JJ MCKENDRICK

Abstract 3580, poster number H9

Phase II study of capecitabine, oxaliplatin and erlotinib in previously treated patients with metastatic colorectal cancer (MCRC)
JA MEYERHARDT

Abstract 3585, poster number J3

A phase 1b dose-escalation trial of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer (MCRC) patients
JP DELORD

Abstract 3602, poster number K9

Capecitabine (X) plus irinotecan (XELIRI) as first-line treatment for metastatic colorectal cancer (MCRC): final safety findings from a phase II trial
YZ PATT

Abstract 3610, poster number L6

Final analysis of irinotecan (CPT-11) and capecitabine (X) as first-line treatment of locally advanced (LA) or metastatic colorectal cancer (MCRC)
A MUÑOZ

Sunday 6 June

08.00–12.00

R06 (2nd floor - escalators 1 & 2)

Poster discussion: Gastrointestinal (colorectal) cancer

Abstract 3520, poster number 11

Correlation of thymidine phosphorylase (TP), thymidylate synthase (TS), and dihydropyrimidine dehydrogenase (DPD) expression in primary and metastatic sites with response to capecitabine plus irinotecan in patients with colorectal cancer
NJ MEROPOL

13.00–17.00

Hall A (right half)

General poster session: Patient care

Abstract 8119, poster number X7

Effects of capecitabine (X) on quality of life (QoL) in patients (pts) with metastatic colorectal cancer
CA MENDONÇA BEATO

Abstract 8120, poster number X8

The impact of the irinotecan (IRI) schedule on quality of life in combination with capecitabine (CAP) in first-line treatment of metastatic colorectal cancer (MCC): a randomized phase II trial of the Swiss Group for Clinical Cancer Research
MM BORNER

13.45–14.00

Hall G

Oral presentation: Gastrointestinal (colorectal) cancer

Abstract 3509

Capecitabine (X) vs bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT study): efficacy results of a phase III trial
J CASSIDY

Tuesday 8 June

08.00–12.00

275

(Escalators 5 & 6)

Poster discussion: Developmental therapeutics: cytotoxic chemotherapy

Abstract 2013, poster number 3

Genotyping to predict for response and toxicity to capecitabine in advanced colorectal cancer patients (pts)
R SHARMA

Notes

CERA

Sunday 6 June

08.00–12.00

Hall A (right half)

General poster session: Hematological malignancies**Abstract 6552, poster number F7**

CERA (Continuous Erythropoiesis Receptor Activator) in patients with multiple myeloma: an exploratory phase I-II dose escalation study
A DMOZYNSKA

MABTHERA®

Saturday 5 June

08.15–08.30

C2 (Entrance inside The Atrium Restaurant)

Integrated education session: Biomarkers for monitoring drug effects**Abstract 2502**

Structural changes in the internal domain of the CD20 antigen is associated with the development of rituximab resistance: effects on signaling and redistribution of CD20 into lipid raft domains in rituximab-resistant cell lines (RRCL)
AC GOWDA

13.00–17.00

R06 (2nd floor – escalators 1 & 2)

General poster session: Central nervous system tumors**Abstract 1518, poster number 9**

Combined immunochemotherapy with reduced dose whole brain radiotherapy (WBRT) for newly diagnosed patients with primary CNS lymphoma (PCNSL)
FG EL KAMAR

Abstract 1521, poster number 12

Intraventricular application of rituximab as a treatment option in patients with CNS lymphoma and leptomeningeal disease
H SCHULZ

13.00–13.15

283

(Escalator 7)

Oral presentation: Lymphoma, including transplantation**Abstract 6500**

Randomized intergroup trial of first line treatment for patients ≤ 60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab – early stopping after the first interim analysis
MGM PFREUNDSCHUH

13.15–13.30

Abstract 6501

Effect of the addition of rituximab to front line therapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) on the remission rate and time to treatment failure (TTF) compared to CHOP alone in mantle cell lymphoma (MCL): results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)
W HIDDEMAN

13.30–13.45

Abstract 6502

Results of E1496: a phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL)
HS HOCHSTER

13.45–14.00

Discussion

Rituximab chemotherapy combinations as first-line therapy for non-Hodgkin's lymphoma
JP LEONARD

13.00–17.00

291

(Escalator 7)

Poster discussion: Lymphoma, including transplantation**Abstract 6519, poster number 2**

Phase II trial of rituximab and short duration chemotherapy followed by 90Y-ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: a Minnie Pearl Cancer Research Network phase II trial
DL SHIPLEY

Abstract 6526, poster number 9

CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma (DLBCL)
KS WILSON

Abstract 6529, poster number 12

CHOP and DHAP plus rituximab followed by autologous stem cell transplantation (ASCT) in mantle cell lymphoma (MCL): a pilot study from the GELA
R DELARUE

Abstract 6534, poster number 17

Rituximab and interleukin 2 (IL2) as treatment for CD20+ non-Hodgkin's lymphoma (NHL) following autologous peripheral blood stem cell transplant (ASCT)
LA HOLMBERG

Sunday 6 June

08.00–12.00

Hall A (right half)

General poster session: Hematologic malignancies**Abstract 6556, poster number F11**

Polymorphisms in Fc γ RIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia
SPTREON

Abstract 6557, poster number G1

Pentostatin, cyclophosphamide and rituximab is an active regimen with low toxicity for previously treated patients with B-cell chronic lymphocytic leukemia and Waldenström's macroglobulinemia
M HENSEL

Abstract 6565, poster number G9

Chemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) improves complete response (CR), remission duration and survival as initial therapy of chronic lymphocytic leukemia (CLL)
MJ KEATING

Abstract 6568, poster number H1

Pentostatin and cyclophosphamide compared to pentostatin, cyclophosphamide, and rituximab as salvage therapy for patients with chronic lymphocytic leukemia
MA WEISS

Abstract 6569, poster number H2

Safety and efficacy of pentostatin and rituximab in patients with low-grade B-cell non-Hodgkin's lymphoma, including chronic lymphocytic leukemia (Protocol N007)
RR MENA

Abstract 6572, poster number H5

Oblimersen sodium (Bcl-2 antisense) plus rituximab in patients with recurrent B-cell non-Hodgkin's lymphoma: preliminary phase II results
B PRO

Abstract 6577, poster number H10

Randomized phase II study of concurrent and sequential combinations of rituximab (R) plus CHOP (R-CHOP) in untreated indolent B-cell non-Hodgkin's lymphoma (B-NHL)
K TOBINAI

Abstract 6579, poster number J1

Multi-centre, phase II study of combination antibody therapy with epratuzumab plus rituximab in relapsed/refractory indolent and aggressive NHL: promising preliminary results
SJ STRAUSS

Abstract 6580, poster number J2

Initial results of a pilot study of epratuzumab and rituximab in combination with CHOP chemotherapy (ER-CHOP) in previously untreated patients with diffuse large B-cell lymphoma (DLBCL)
IN MICALLEF

Sunday 6 June (cont'd)

Notes

08.00–12.00

Hall A (right half)

General poster session: Hematologic malignancies

Abstract 6583, poster number J5

Durable remissions after rituximab plus thalidomide for relapsed/refractory mantle cell lymphoma
J DRACH

Abstract 6584, poster number J6

Feasibility and preliminary efficacy of R-CHOP-14 in patients with diffuse large B-cell lymphoma (DLBCL)
JL HALAAS

Abstract 6591, poster number K2

NCCTG trial of concomitant or sequential IL-12 in combination with rituximab in previously treated non-Hodgkin lymphoma patients
SM ANSELL

Abstract 6592, poster number K3

Rituximab, gemcitabine and oxaliplatin (R-GEMOX): a promising regimen for refractory/relapsed B-cell lymphoma
T EL GNAOUI

Abstract 6593, poster number K4

Results from a phase I study of intraventricular administration of rituximab in patients with recurrent lymphomatous meningitis
JL RUBENSTEIN

08.00–12.00

Hall A (right half)

General poster session: Transplantation

Abstract 6662, poster number Y5

Front-line high-dose chemotherapy (HDT) combined with rituximab for adults with aggressive large B cell lymphoma (DLBCL). A pilot study by the GOELAMS
NJ MILPIED

AVASTIN™

Saturday 5 June

08.45–09.00

Hall I1

Integrated education session: Targeting the VEGF and related pathways: preliminary activity in renal cell cancer

Abstract 4502

Phase II trial of bevacizumab and erlotinib in patients with metastatic renal carcinoma (RCC)

JD HAINSWORTH

13.00–17.00

Hall A (right half)

General poster session: Gastrointestinal (noncolorectal) cancer

Abstract 4088, poster number U3

Bevacizumab in hepatocellular carcinoma in patients without metastasis and without invasion of the portal vein

JD SCHWARTZ

13.30–17.30

356 (Escalators 3 & 4)

Poster discussion: Sarcoma

Abstract 9012, poster number 4

Cardiac toxicity in a phase II study of doxorubicin (DOX) and bevacizumab (BEV) for patients (pts) with metastatic soft-tissue sarcomas (STS)

DR D'ADAMO

16.15–16.30

La Louisiane Ballroom (hall A lobby)

Integrated education session: Targeting cancer: antibodies versus small molecules
Abstract 2000

Phase I/II trial evaluating the anti-VEGF MAb bevacizumab in combination with erlotinib, a HER1/EGFR-TK inhibitor, for patients with recurrent non-small cell lung cancer

A SANDLER

Sunday 6 June

08.00–12.00

291 (Escalator 7)

Poster discussion: Developmental therapeutics: molecular therapeutics
Abstract 3013, poster number 4

Rapid decrease in blood flow (BF), blood volume (BV), and vascular permeability (PS) in carcinoid patients treated with bevacizumab

JC YAO

08.00–12.00

Hall A (right half)

General poster session: Head and neck cancer
Abstract 5539, poster number A1

Phase I study of epidermal growth factor receptor (EGFR) inhibitor, erlotinib, and vascular endothelial growth factor monoclonal antibody, bevacizumab, in recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN)

A MAUER

Monday 7 June

09.30–10.45

271 (Escalators 5 & 6)

Special session: High-priority cooperative group phase III trials for community practitioners

Clinical trials: CALB 90206: a phase III trial of interferon-alpha (IFNA) or INFA plus bevacizumab in advanced renal carcinoma

SS GRUBBS, S HALABI, BI RINI

Tuesday 8 June

08.00–12.00

391 (Escalator 7)

Poster discussion: Gastrointestinal (noncolorectal) cancer
Abstract 4009: poster number 1

Bevacizumab (B) plus gemcitabine (G) in patient (pts) with advanced pancreatic cancer (PC): updated results of a multi-center phase II trial

HL KINDLER

BONDRONAT®

Abstract 1492

Effect of 1-year intravenous ibandronate treatment on time to serum creatinine increase in patients with skeletal metastases from breast cancer

IJ DIEHL

Publication, refer to abstract book

Abstract 1514

Safety of an intravenous (i.v.) dose of ibandronate followed by daily oral dosing in metastatic bone disease: results of an open-label study

J-J BODY

Publication, refer to abstract book

HERCEPTIN®

Sunday 6 June

08.00–12.00

Hall A (right half)

Poster discussion: Tumor biology and human genetics

Abstract 9559, poster number AA10

HER-2/neu overexpression and its effect on survival in solid tumors

KTENDULKAR

KYTRIL®

Tuesday 8 June

08.00–12.00

R06 (2nd floor – escalators 1 & 2)

Poster discussion: patient care II

Abstract 8048, poster number 10

A meta-analysis comparing the efficacy of five 5-HT₃-receptor antagonists (5-HT₃-RAs) for acute chemotherapy induced emesis

KJORDAN

Abstract 1467

Cardiovascular safety of the 5-HT₃-receptor antagonists readdressed

D TALBOT

Publication, refer to abstract book

ROFERON®

Sunday 6 June

13.00–17.00

Hall A (right half)

General poster session: Genitourinary cancer
Abstract 4604, poster number G3

A phase II trial of interferon-alpha and celecoxib in metastatic renal carcinoma: clinical and anti-angiogenic effects

BI RINI

Abstract 4607, poster number G6

A randomized phase III trial of low dose versus intermediate dose interferon alfa (IFN) as front-line therapy in advanced progressive renal cell cancer (RCC)

NM TANNIR

Monday 7 June

09.30–10.45

271 (Escalators 5 & 6)

Special session: High-priority cooperative group phase III trials for community practitioners

Clinical trials: CALB 90206: a phase III trial of interferon-alpha (IFNA) or INFA plus bevacizumab in advanced renal carcinoma

SS GRUBBS, S HALABI, BI RINI

TARCEVA™

Saturday 5 June

08.00–12.00

Hall A (right half)

General poster session: Lung cancer
Abstract 7080, poster number R1

Preliminary results from a phase II study of the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in patients >70 years of age with previously untreated advanced non-small cell lung carcinoma

BE JOHNSON

TARCEVA™

Saturday 5 June (cont'd)

08.00–12.00

Hall A (right half)

General poster session: Lung cancer
Abstract 7085, poster number R6

Weekly high-dose erlotinib in patients with non-small cell lung cancer (NSCLC): a phase I/II study
DT MILTON

Abstract 7143, poster number W9

Apoptotic effects of the docetaxel→OSI-774 combination in non-small cell lung carcinoma (NSCLC) cells
T KIMURA

08.45–09.00

Hall I1

Integrated education session: Targeting the VEGF and related pathways: preliminary activity in renal cell cancer
Abstract 4502

Phase II trial of bevacizumab and erlotinib in patients with metastatic renal carcinoma (RCC)
JD HAINSWORTH

13.00–17.00

Hall A (right half)

General poster session: Gastrointestinal (noncolorectal) cancer
Abstract 4077, poster number T3

OSI-774 in advanced esophageal cancer: a phase II study
D RADOVICH

Abstract 4093, poster number U8

Erlotinib, gemcitabine, paclitaxel and radiation for locally advanced pancreatic cancer: a phase I study
D IANNITTI

Abstract 4110, poster number W3

Erlotinib + gemcitabine in patients with unresectable pancreatic carcinoma: results from a phase IB trial
BW PORTERFIELD

13.45–17.45

391 (Escalator 7)

Poster discussion: Lung cancer I
Abstract 7026, poster number 3

Determinants of sensitivity to the EGFR TK inhibitor erlotinib (E) in a panel of NSCLC cell lines
R PEREZ-SOLER

Abstract 7028, poster number 5

Schedule-dependent interaction between epidermal growth factor inhibitors (EGFRI) and G2/M blocking chemotherapeutic agents (G2/MB) on human NSCLC cell lines in vitro
B PIPERDI

16.15–16.30

La Louisiane Ballroom (hall A lobby)

Integrated education session: Targeting cancer: antibodies versus small molecules
Abstract 2000

Phase I/II trial evaluating the anti-VEGF MAbs bevacizumab in combination with erlotinib, a HER1/EGFR-TK inhibitor, for patients with recurrent non-small cell lung cancer
A SANDLER

Sunday 6 June

08.00–12.00

Hall A (right half)

General poster session: Head and neck cancer
Abstract 5539, poster number A1

Phase I study of epidermal growth factor receptor (EGFR) inhibitor, erlotinib, and vascular endothelial growth factor monoclonal antibody, bevacizumab, in recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN)
A MAUER

Abstract 5541, poster number A3

Phase I and II study of OSI-774 and docetaxel in squamous cell carcinoma of the head and neck (SCCHN)
CA RHOADES

08.15–08.30

R04 (2nd floor – escalators 1 & 2)

Oral presentation: Central nervous system tumors

Abstract 1502

A phase II trial of erlotinib (OSI-774) in patients (pts) with recurrent malignant gliomas (MG) not on EIAEDs
JJ RAIZER

13.00–13.15

Hall I1

Oral presentation: Developmental therapeutics: molecular therapeutics
Abstract 3007

Molecular correlates of the EGFR signaling pathway in association with SWOG S0218: a phase II study of oral EGFR tyrosine kinase inhibitor OSI-774 (NSC-718781) in patients with malignant pleural mesothelioma (MPM)
L GARLAND

13.00–17.00

Hall A (right half)

General poster session: Central nervous system tumors

Abstract 1555, poster number B10

Erlotinib HCL for glioblastoma multiforme in first relapse, a phase II trial
A YUNG

Abstract 1558, poster number C2

Phase II trial of the EGFR tyrosine kinase inhibitor erlotinib for single agent therapy of recurrent glioblastoma multiforme: interim results
MA VOGELBAUM

13.45–17.45

391 (Escalator 7)

Poster discussion: Lung cancer II
Abstract 7061, poster number 12

Long survival of never smoking non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib HCl (OSI-774) and chemotherapy: sub-group analysis of TRIBUTE
VA MILLER

Abstract 7062, poster number 13

Cigarette smoking history predicts sensitivity to erlotinib: results of a phase II trial in patients with bronchioloalveolar carcinoma (BAC)
MG KRIS

Monday 7 June

07.45–09.00

293 (Escalator 7)

Scientific symposium: Early indicators of clinical effect

Assessing inhibitors of EGFR signal transduction
M HIDALGO

08.00–12.00

Hall A (right half)

General poster session: Developmental therapeutics: cytotoxic chemotherapy
Abstract 2050, poster number B4

Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial of paclitaxel (Pac) and carboplatin (C) combined with erlotinib (E) or placebo in patients with advanced non-small cell lung cancer (NSCLC)
HTTRAN

08.00–12.00

Hall A (right half)

General poster session: Developmental therapeutics: molecular therapeutics
Abstract 3050, poster number L11

Durable disease stabilization and antitumor activity with OSI-774 in renal cell carcinoma: a phase II, pharmacokinetic (PK) and biological correlative study with FDG-PET imaging
M BEERAM

Abstract 3053, poster number M3

Phase I trial of OSI-774 and CPT-11 in patients with advanced solid tumors
RD RAO

TARCEVA™

Monday 7 June (cont'd)

08.00–12.00

275 (Escalators 5 & 6)

Poster discussion: Gynecologic cancer
Abstract 5017, poster number 9

A phase Ib trial of erlotinib (E) in combination with docetaxel (D) and carboplatin (C) in untreated ovarian, fallopian tube and primary peritoneal cancers
P VASEY

Abstract 5019, poster number 11

Phase II study of erlotinib (OSI 774) in women with recurrent or metastatic endometrial cancer: NCIC CTG IND-148
KV JASAS

09.15–09.30

Auditorium (2nd Floor–escalators 6&7)

Oral presentation: Lung Cancer II
Abstract 7022

A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC) FA SHEPHERD

09.30–09.45

Abstract 7010

Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC)
U GATZEMEIER

09.45–10:00

Abstract 7011

TRIBUTE – a phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC)
RS HERBST

Tuesday 8 June

07.45–09.00

271 (Escalators 5 & 6)

Scientific symposium: Early indicators of clinical effect

Assessing inhibitors of EGFR signal transduction
M HIDALGO

08.00–12.00

391 (Escalator 7)

Poster discussion: Gastrointestinal (noncolorectal) cancer

Abstract 4025, Poster number 17

Phase II trial of erlotinib (OSI-774) in patients with hepatocellular or biliary cancer
PA PHILIP

XELODA®

Saturday 5 June

13.00–17.00

Hall A (right half)

General poster session: Gastrointestinal (noncolorectal) cancer

Abstract 4047, poster number P11

Capecitabine (X) combined with cisplatin (P) as 1st-line therapy in Chinese patients (pts) with advanced gastric cancer (AGC)
M JIN

Abstract 4051, poster number Q4

A phase II study of paclitaxel and capecitabine combination chemotherapy in patients with advanced gastric cancer as a first-line therapy
HJ KANG

Abstract 4057, poster number R5

A phase II study of weekly docetaxel (T) and capecitabine (X) in patients with metastatic gastric cancer (GC)
HK KIM

Abstract 4066, poster number S3

A phase I/II trial of docetaxel, capecitabine, and cisplatin as a first line chemotherapy for advanced gastric cancer
Y-K KANG

Abstract 4074, poster number S11

Epirubicin (E), cisplatin (C) and capecitabine (X) in first-line chemotherapy for patients with advanced gastric cancer
EK CHO

Abstract 4091, poster number U6

A multicenter phase II study of capecitabine plus oxaliplatin (CapOx) in advanced biliary system adenocarcinomas
O NEHLS

Abstract 4104, poster number V8

Up-regulation of thymidine phosphorylase (TP) by radiotherapy (RT): a phase I study of capecitabine (CAP) with concurrent RT for pts with locally advanced (LA) pancreatic cancer (Pan Ca)
MW SAIF

Abstract 4108, poster number W1

Randomised trial of capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (GemOx) in advanced pancreatic cancer
V HEINEMANN

Sunday 6 June

13.00–17.00

Hall A (right half)

General poster session: Patient care

Abstract 8105, poster number W4

Novel & effective management of capecitabine induced Hand Foot Syndrome
D PENDHARKAR

13.00–17.00

Hall A (right half)

General poster session: Patient care
Abstract 8160, poster number BB4

Preservation of Activities Daily Living (ADL) in a phase-II impact study of oral capecitabine and vinorelbine in the treatment of metastatic carcinomas in patients 70 and older: the GERICO-01 Study by the French FNCLCC Group
AC BRAUD

Monday 7 June

08.00–12.00

Hall A (right half)

General poster session: Developmental therapeutics: molecular therapeutics

Abstract 3070, poster number N9

Phase I clinical, biology & pharmacokinetic study of the combination of GW 572016 and capecitabine in patients with advanced solid tumors
G SCHWARTZ

08.00–12.00

Hall A (right half)

General poster session: Developmental therapeutics: cytotoxic chemotherapy

Abstract 2042, poster number A7

Phase I dose escalation and safety study of a semi-solid matrix (SSM) formulation of oral irinotecan and capecitabine tablets in patients with advanced solid tumors
AB BENSON

08.30–08.45

B2 (hall B lobby)

Oral presentation: Genitourinary (nonprostate) cancer

Abstract 4515

A phase II study of gemcitabine (G) and capecitabine (C) in patients with metastatic renal cell cancer (mRCC): a report of Cancer and Leukemia Group B #90008
WM STADLER